Therapeutic antibodies have helped millions of people, including our own family members. Even though they are highly effective medicines, 90% of the antibodies being tested in labs today will fail to make it to clinical trials. Those that are approved by the FDA must pay for the failures - resulting in antibody therapies with costs of over $100,000.
Our mission is to leverage advances in computation to EVQLVe the cost and time of developing these life-changing therapies. We do this by failing in the computer, where it’s fast and scalable, as opposed to the lab, where it’s capital intensive, time consuming, and risky. We love to prove our skeptics wrong, and will keep doing it as we accelerate healing to those in need.
Therapeutic antibodies have been revolutionary in helping many people, however they can be ineffective in as many as 50% of patients. That’s because medicines are designed to work best for the greatest number of people - not to be most effective for you. With over 75% of doctor's visits leading to a one-size-fits-all prescription, the scale and urgency of this oversight requires new ways of thinking.
We envision a future where your doctor will design a medicine specifically for you - one that will work best for you, one that may only work for you. That is the dream of personalized medicine. And while reaching that future could take decades, an essential step is teaching computers to create medicines today. That is precisely what we work towards, everyday, here at EVQLV.
CEO & Co-Founder
CTO & Co-Founder
Chief Business Officer
Finance & Operations
Vikas Goyal is a biotech entrepreneur and investor, with a particular focus on corporate strategy, capital formation, and corporate partnerships for early-stage therapeutics companies.
Most recently, Vikas was SVP of Business Development for Pandion Therapeutics. He initially joined Pandion as a Board member and investor in 2018, then joined the company full-time in 2019 taking the company through a research collaboration with Astellas, an IPO, and the company’s acquisition by Merck for $1.85 billion in 2021. Prior to Pandion, Vikas worked as an investor at SR One, at the time the corporate venture capital arm of GlaxoSmithKline, where he started as an intern while attending Wharton. During his time at SR One, Vikas invested in and served on the boards of nearly 20 early-stage biotech companies including Morphic Therapeutics (Nasdaq: MORF), River Vision Development (acquired by Horizon), Nimbus Therapeutics, Turning Point (acquired by BMS), Spero Therapeutics (Nasdaq: SPRO) and Pandion. Earlier in his career, Vikas was a Consultant at McKinsey, a co-founder of Extera Partners, and a Business Development Manager at Infinity Pharmaceuticals.